Kerb R, Brinkmann U
Epidauros Biotechnologie AG, Am Neuland, Bernried, Germany.
Pharmacogenomics. 2001 Aug;2(3):303-5. doi: 10.1517/14622416.2.3.303.
Pharmacogenomics promises to offer distinct strategic advantages to pharmaceutical companies, physicians, providers and patients. Cambridge Healthtech Institute's 2nd Annual Conference on 'Pharmacogenomics Europe: Presaging Profits' covered all aspects of pharmacogenomics and gave scientists from both academia and from pharmaceutical and biotech companies a great opportunity to discuss the latest progress in pharmacogenomic research. The meeting considered technologies for single nucleotide polymorphism (SNP) screening and expression profiling, bioinformatic tools for data evaluation and gave an overview on the state of affairs and novel approaches to implement pharmacogenomics and pharmacogenetics into drug development and medical treatment. The major strength of the meeting was the merging of scientists from many different disciplines, such as clinicians, pharmacologists, molecular biologists, engineers and bioinformatics experts, into one meeting.
药物基因组学有望为制药公司、医生、医疗服务提供者和患者带来显著的战略优势。剑桥健康科技研究所举办的第二届“欧洲药物基因组学：预示利润”年度会议涵盖了药物基因组学的各个方面，为来自学术界以及制药和生物技术公司的科学家提供了一个绝佳的机会，来讨论药物基因组学研究的最新进展。会议探讨了单核苷酸多态性（SNP）筛查技术和表达谱分析技术、用于数据评估的生物信息学工具，并概述了将药物基因组学和药物遗传学应用于药物开发和医疗治疗的现状及新方法。此次会议的主要亮点在于，将来自许多不同学科的科学家，如临床医生、药理学家、分子生物学家、工程师和生物信息学专家汇聚到了一场会议中。
